section name header

Interacting Drugs

OBJECT DRUGS

PRECIPITANT DRUGS

Antimicrobials:


Comment:

Lomitapide is metabolized by CYP3A4, and inhibitors of CYP3A4 can produce dramatic increases in lomitapide plasma concentrations. For example, the strong CYP3A4 inhibitor, ketoconazole, produced a 27-fold increase in lomitapide AUC. Because increased lomitapide plasma levels can cause substantial toxicity, particularly hepatotoxicity, combining lomitapide with strong (or moderate) CYP3A4 inhibitors is considered contraindicated.


Class 1: Avoid Combination